Galmed Pharmaceuticals Sets Shareholder Meeting for Oct 14

Ticker: GLMD · Form: 6-K · Filed: Sep 20, 2024 · CIK: 1595353

Galmed Pharmaceuticals LTD. 6-K Filing Summary
FieldDetail
CompanyGalmed Pharmaceuticals LTD. (GLMD)
Form Type6-K
Filed DateSep 20, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: shareholder-meeting, corporate-governance

TL;DR

Galmed calling shareholder meeting Oct 14 - expect votes on key company moves.

AI Summary

Galmed Pharmaceuticals Ltd. announced on September 20, 2024, that it will hold a Special General Meeting of Shareholders on Monday, October 14, 2024, at 5:00 p.m. Israel time. The meeting will take place at the offices of Meitar Law Offices in Ramat Gan, Israel. Shareholders will receive a Notice of the Special General Meeting, Proxy Statement, and Proxy Card.

Why It Matters

This meeting is a crucial step for Galmed to potentially make significant corporate decisions that could impact its future direction and shareholder value.

Risk Assessment

Risk Level: low — The filing is an administrative announcement of a shareholder meeting, not a financial event or strategic shift.

Key Players & Entities

FAQ

What is the purpose of the Special General Meeting of Shareholders?

The filing does not specify the exact agenda items for the Special General Meeting, only that a Notice and Proxy Statement will be provided.

When and where will the Special General Meeting be held?

The meeting is scheduled for Monday, October 14, 2024, at 5:00 p.m. Israel time, at the offices of Meitar Law Offices in Ramat Gan, Israel.

Who is providing legal counsel to Galmed Pharmaceuticals Ltd. for this meeting?

Meitar Law Offices is serving as the legal counsel to the Company.

What documents will shareholders receive regarding the meeting?

Shareholders will receive a Notice of the Special General Meeting of Shareholders, a Proxy Statement, and a Proxy Card.

Is this Galmed's first report of this nature for September 2024?

The filing is designated as 'Report No. 2' for the month of September 2024.

Filing Stats: 282 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2024-09-20 16:46:04

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Galmed Pharmaceuticals Ltd. Date: September 20, 2024 By: /s/ Allen Baharaff Allen Baharaff President and Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing